Mission
The purpose of the REPAIR Impact Fund is to increase humanity’s therapeutic arsenal in the fight against antimicrobial resistance.
The purpose of the REPAIR Impact Fund is to increase humanity’s therapeutic arsenal in the fight against antimicrobial resistance.
Novo Holdings established the REPAIR Impact Fund commissioned by the Novo Nordisk Foundation in February 2018 with a total budget of USD 165 million to invest in companies involved in discovering and the early-stage development of therapies targeting resistant microorganisms.
The fund is expected to invest USD 20 million to 40 million per year over 3–5 years in about 20 projects, which is anticipated to yield at least one new therapy reaching the market.
The REPAIR Impact Fund will invest in start-ups, early-stage companies and corporate spin-outs. Our philosophy is to support ambitious programmes addressing antimicrobial resistance through a broad range of therapeutic modalities.
REPAIR is an acronym: Replenishing and Enabling the Pipeline for Anti-Infective Resistance.
As a part of Novo Holdings, the REPAIR Impact Fund offers:
Novo Holdings is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation.
Established in 1999, Novo Holdings is the holding company of the Novo Group and manages the Foundation’s assets.
The Novo Nordisk Foundation is an independent Danish foundation with corporate interests.
The Foundation has two objectives: 1) to provide a stable basis for the commercial and research activities of the companies in the Novo Group; and 2) to support scientific, humanitarian and social causes.
The REPAIR Impact Fund expects to invest in about 20 projects over 3–5 years. The portfolio build-up and its progress can be followed here.
Novo Holdings A/S
Tuborg Havnevej 19
2900 Hellerup
Denmark
repair@novo.dk